Background: EULAR recommendations advocate MTX as first line therapy. For patients (pts) who fail to attain remission or low disease activity (LDA) after 6 months of MTX treatment, TNF inhibitors should be added to the therapeutic regimen in pts with high risk of bad outcome. This post hoc analysis examined outcomes following open label (OL)-adalimumab (ADA) þ MTX in RA pts who did not achieve a stable LDA target at 22 and 26 weeks either from ADA þ MTX or MTX monotherapy. Consequences of optimizing or not optimizing therapy were assessed. Methods: OPTIMA was a 78 week, randomized, double-blind, doubletreatment period study designed to compare safety and efficacy of ADA þ MTX with placebo (PBO) þ MTX in early RA pts. Following ADA þ MTX or PBO þ MTX treatment for 26 weeks (Period-1), nonresponders (NR) were defined as pts failing to achieve a stable LDA target of DAS28(CRP) <3.2 at week 22 and week 26 and given OL-ADA þ MTX for an additional 52 weeks (Period-2) (OL-ADA Carry On and Rescue-ADA arms, respectively). Period-2 responders were defined as those achieving LDA at week 52 following OL-ADA þ MTX therapy. Logistic regression analysis was conducted with baseline and week 26 disease characteristics as variables. Results: Compared with responders, Period-1 NR began the study with higher overall disease activity. Among these, 78/259 (30%) OL-ADA Carry On and 157/348 (45%) Rescue-ADA pts achieved DAS28 (CRP) <3.2 following 26 weeks of OL-ADA þ MTX therapy; 33/ 259 (13%) and 49/348 (14%) OL-ADA Carry On and Rescue-ADA pts, respectively, had DAS28 (CRP) 3.2 at week 52 and achieved DAS28 (CRP) <3.2 at week 78. Mean values of responders' clinical, radiographic, and functional outcomes were much lower than those of NR and were similar to those seen for pts who achieved the treatment target within Period-1. This indicates that starting with MTX followed by ADA in insufficient responders to MTX is an appropriate strategy; a small subset of pts responds more slowly to MTX/ADA combination from start (Table 1) . ACR20/50/70 scores for the Rescue-ADA arm from week 26 to week 78 were sizeable (51%, 34%, and 19%, respectively). OL-ADA Carry On arm achieved ACR20/50/70 from week 26 baseline in 27%, 15%, and 8% of pts, respectively, at week 78. Age, patient and physician's global assessment of disease, and tender/swollen joint counts were all predictors of achieving DAS28 (CRP) <3.2 at week 78. Conclusion: When advanced to OL-ADA þ MTX therapy, pts initially not achieving stable LDA target at week 26 following MTX monotherapy demonstrated improvements in clinical and functional outcomes at week 52 and week 78, structural progression was minimal. Some improvement was also seen among pts who did not yet attain stable LDA at week 26 on ADA þ MTX but continued this treatment; however, it remains unknown whether pts who were not in LDA at week 78 might have benefited from earlier treatment adjustment in an attempt to further improve outcomes. Disclosure statement: J.S.S. has received consulting fees from AbbVie Inc., Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Glaxo, Lilly, Pfizer, MSD, Novo-Nordisk, Roche, Sandoz and UCB; and has received funding from AbbVie Inc., Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Glaxo, Lilly, Pfizer, MSD, Novo-Nordisk, Roche, Sandoz and UCB. R.F.v.V. has received consulting fees from AbbVie Inc., Biotest, BMS, Glaxo, Lilly, MSD, Pfizer, Roche, UCB and Vertex; and has received funding from AbbVie Inc., Biotest, BMS, Glaxo, Lilly, MSD, Pfizer, Roche, UCB and Vertex. R.F. has received consulting fees from AbbVie Inc., Pfizer, Merck, Roche, UCB, Celgene, CentocorJanssen, Amgen, AstraZeneca, BMS, Lilly, Sanofi-Aventis and Novartis; and has received funding from AbbVie Inc., Pfizer, Merck, Roche, UCB, Celgene, Centocor-Janssen, Amgen, AstraZeneca, BMS, Lilly, SanofiAventis and Novartis. P.E. has received consulting fees from AbbVie Inc., Merck, Pfizer, UCB, Roche, and BMS; and has received funding from AbbVie Inc., Merck, Pfizer, UCB, Roche and BMS. S.F. is an employee of AbbVie and may hold stock and/or options. S.S.R. is an employee of AbbVie and may hold stock and/or options. A.C. is an employee of AbbVie and may hold stock and/or options. H.K. is an employee of AbbVie and may hold stock and/or options. A.K. has received consulting fees from AbbVie Inc., Amgen, Astra-Zeneca, BMS, Celgene, CentocorJanssen, Pfizer, Roche and UCB; and has received funding from AbbVie Inc., Amgen, Astra-Zeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche and UCB. Background: Adalimumab is a fully human monoclonal antibody known to be effective in the treatment of RA. Previous studies have reported that after an initial response, some RA patients may lose response to adalimumab over time. One explanation is immunogenicity of adalimumab leading to the development of antibodies against the drug. Radioimmunoassay (RIA) is a sensitive method to detect anti-drug antibodies (ADAb). The aim was to use RIA to evaluate the occurrence of antibodies against adalimumab in a cohort of RA 88 
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